VivoSeq
Psychiatry

Treatment Resistant Depression (TRD)

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Treatment Resistant Depression (TRD) is an early-stage landscape with 0 programs across 2 companies. The most active players are Merck & Co., Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Terminated1 · 17%
Approved for marketing1 · 17%
Not yet recruiting1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Resistant Depression and Vagus Nerve Stimulation : a Medico-economic, Multicenter, Randomized and Open Trial
Recruiting·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT05952674·166 enrolled
Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression
Not yet recruiting·GGulhane Training and Research Hospital·Preclinical·NCT07673913·100 enrolled
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Completed·MMassachusetts General Hospital·Phase 2·NCT01920555·99 enrolled
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
Completed·MMassachusetts General Hospital·Phase 4·NCT03149991·51 enrolled
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
Terminated·Merck & Co. logoMerck & Co.·Phase 2·NCT04663321·99 enrolled
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Approved for marketing·Johnson & Johnson logoJohnson & Johnson·N/A·NCT03829579

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)